The newly formed vaccines subsidiary of CDMO WuXi Biologics will create 200 jobs at a site in Ireland.

Dan Stanton, Managing editor

November 26, 2019

2 Min Read
WuXi Vaccines invests $240m in plant at ‘Ireland’s largest construction site’
Image: iStock/Niyazz

The newly formed vaccines subsidiary of CDMO WuXi Biologics will create 200 jobs at a site in County Louth, Ireland.

Bioprocess Insider reported last month that WuXi Vaccines – a joint venture between WuXi Biologics and Hile Bio-Technology – had applied for planning permission to build a three-storey manufacturing facility in Dundalk, County Louth.

Now the firm and Ireland’s Industrial Development Authority (IDA) have revealed the level of investment in the vaccine facility will be $240 million (€218 million) and bring 200 jobs to the area.


Image: iStock/Niyazz

Eileen Sharpe, from the IDA Ireland said this investment “will considerably strengthen our life sciences ecosystem and reinforce Ireland’s strong drug manufacturing capabilities. The additional 200 jobs being created by the WuXi Vaccines project will provide a substantial further boost to the economy of not just County Louth, but the whole North East region.”

The facility will be built adjacent to a production site being constructed by parent company WuXi Biologics. The contract development and manufacturing organization (CDMO) broke ground on the €325 million single-use biologics plant in 2018. The site is the first production site outside of China for the drugmaker, which has since expanded into Singapore and the US.

According to an IDA spokesperson, the site in Dundalk is “the biggest construction site in Ireland at the moment.”

Vaccine CDMO

WuXi Vaccines was formed in May 2019 to service a Letter of Intent (LOI) inked with a multinational vaccine company said to be worth more than $3 billion.

“Due to process complexity, extensive analytic testing and rigorous regulatory standards, vaccines are difficult to manufacture, and process and quality control are extremely critical for the quality of the product,” WuXi Biologics CEO Chris Chen said.

“This new project to exclusively manufacture a vaccine for the global market is among the first of its kind in the industry and is a further testimony to the technical strengths and premier quality which WuXi Biologics will bring to Dundalk.”

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like